Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

NCT00398320 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: Capecitabine
DRUG: Oxaliplatin
DRUG: Bevacizumab

Sponsor

Pamela L. Kunz